FDA Questions Actavis on Contraceptive Patch
Actavis said Tuesday that the Food and Drug Administration didn't approve its progestin-only contraceptive patch and wants more information on the drug.
The company said the FDA's questions are mostly regarding the drug's size and formulation. Actavis used one size and formulation in clinical trials and wants to market a different version.
Most birth control drugs use a combination of two female hormones, estrogen and progestin. The company's patch contains only progestin.
U.S.-traded shares of Ireland-based Actavis PLC fell $1.41 to $164.55 in morning trading.